3 December 2021
By Max Holloway

LYPHE Group announces new Medical Advisory Board to assist with Unique Cannabis Healthtech & Research Solutions

Lyphe Group

LYPHE Group, the UK’s leading provider of medical cannabis, has today announced a new Medical Advisory Board (MAB) that is set to revolutionise the medical cannabis market through pharmacy dispensing technologies and patient data frameworks. The MAB is chaired by Europe’s foremost medical cannabis expert, Professor Mike Barnes, and includes some of the region’s leading innovators in cannabinoid science, healthtech and clinical practice.

Work will now begin on building rigorous datasets using the largest pool of active patients in the UK to unearth patterns on tolerability and effectiveness that can assist LYPHE Group’s doctors in optimising clinical pathways.

The MAB shall offer oversight to the business in the ongoing development of proprietary softwares that will set a blueprint for medical cannabis dispensing management across Europe.

The advisors that form the MAB are:

Professor Mike Barnes, Consultant Neurologist and Chair of the Medical Cannabis Clinicians Society who has been the industry leader for change in the UK and further afield. He has trained almost all prescribing doctors in the UK.

Dr Karen Wright, Senior Lecturer in Biomedicine & Principal of Grizedale College at Lancaster University. Dr Wright’s research began with inflammatory cell signalling in the gut, which then progressed to the cellular and molecular mechanisms of the endocannabinoid system in gastrointestinal diseases. Her publications include topics ranging from cannabinoid signalling, wound healing and mucosal barrier function. She collaborates with clinicians, industry and academics to work towards realising the therapeutic potential of cannabis-based medicines.

Farid Poonja, Previous Head of Healthcare Product and Engineering at Walgreens Boots Alliance and a thought leader in the healthtech space. Poonja has delivered large scale digital healthcare transformation projects and platforms in the UK, Europe and USA, including Boots Health Hub and the NHS Electronic Prescription Service. Across Europe  he has overseen the development of various digital tools to support independent pharmacies.

Dr Sunny Nayee, Pain Consultant and Medical Director of The Medical Cannabis Clinics. Dr.Nayee was trained at Cambridge University Medical School before receiving the Strategic Health Authorities Prize. Prescribing medical cannabis to his patients with great success since 2019, Dr.Nayee treats well in excess of 1,000 patients today and is considered to be the leading prescriber of medical cannabis in the UK.

Chris Ashton, Chief Pharmacist at LYPHE Group with more than 20 years of experience in leading roles within the pharmaceutical industry for companies such as Sainsburys, Bullens and Clinigen. Chris is the leading UK pharmacist in the medical cannabis sector and has been instrumental in the supply of medical cannabis to the UK He also serves as Superintendent Pharmacist at LYPHE Group owned, cannabis dispensary, Dispensary Green.

Prof Barnes said of the newly formed MAB, “Since medical cannabis was rescheduled in the UK, LYPHE has been at the forefront of the movement while always focused on the  development of ventures to give patients access to a medicine they so desperately need. I’m honoured to be selected as Chair of the Medical Advisory Board at this pinnacle stage of growth and delighted to be sharing the table with such a talented group of experts in their relevant fields.”